Cargando…

Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial

BACKGROUND: Patient decision aids (P‐DAs) inform medical decision making, but longer term effects are unknown. This article describes extended follow‐up from a thyroid cancer treatment P‐DA trial. METHODS: In this single‐center, parallel‐design randomized controlled trial conducted at a Canadian ter...

Descripción completa

Detalles Bibliográficos
Autores principales: Sawka, Anna M., Straus, Sharon, Rodin, Gary, Heus, Lineke, Brierley, James D., Tsang, Richard W., Rotstein, Lorne, Ezzat, Shereen, Segal, Phillip, Gafni, Amiram, Thorpe, Kevin E., Goldstein, David P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832354/
https://www.ncbi.nlm.nih.gov/pubmed/26195199
http://dx.doi.org/10.1002/cncr.29548
_version_ 1782427242020732928
author Sawka, Anna M.
Straus, Sharon
Rodin, Gary
Heus, Lineke
Brierley, James D.
Tsang, Richard W.
Rotstein, Lorne
Ezzat, Shereen
Segal, Phillip
Gafni, Amiram
Thorpe, Kevin E.
Goldstein, David P.
author_facet Sawka, Anna M.
Straus, Sharon
Rodin, Gary
Heus, Lineke
Brierley, James D.
Tsang, Richard W.
Rotstein, Lorne
Ezzat, Shereen
Segal, Phillip
Gafni, Amiram
Thorpe, Kevin E.
Goldstein, David P.
author_sort Sawka, Anna M.
collection PubMed
description BACKGROUND: Patient decision aids (P‐DAs) inform medical decision making, but longer term effects are unknown. This article describes extended follow‐up from a thyroid cancer treatment P‐DA trial. METHODS: In this single‐center, parallel‐design randomized controlled trial conducted at a Canadian tertiary/quaternary care center, early‐stage thyroid cancer patients from a P‐DA trial were contacted 15 to 23 months after randomization/radioactive iodine (RAI) decision making to evaluate longer term outcomes. It was previously reported that the use of the computerized P‐DA in thyroid cancer patients considering postsurgical RAI treatment significantly improved medical knowledge in comparison with usual care alone. The P‐DA and control groups were compared for the following outcomes: feeling informed about the RAI treatment choice, decision satisfaction, decision regret, cancer‐related worry, and physician trust. In a subgroup of 20 participants, in‐depth interviews were conducted for a qualitative analysis. RESULTS: Ninety‐five percent (70 of 74) of the original population enrolled in follow‐up at a mean of 17.1 months after randomization. P‐DA users perceived themselves to be significantly more 1) informed about the treatment choice (P = .008), 2) aware of options (P = .009), 3) knowledgeable about treatment benefits (P = .020), and 4) knowledgeable about treatment risks/side effects (P = .001) in comparison with controls. There were no significant group differences in decision satisfaction (P = .142), decision regret (P = .199), cancer‐related worry (P = .645), mood (P = .211), or physician trust (P = .764). In the qualitative analysis, the P‐DA was perceived to have increased patient knowledge and confidence in decision making. CONCLUSIONS: The P‐DA improved cancer survivors’ actual and long‐term perceived medical knowledge with no adverse effects. More research on the long‐term outcomes of P‐DA use is needed. Cancer 2015;121:3717–3726. © 2015 American Cancer Society.
format Online
Article
Text
id pubmed-4832354
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-48323542016-04-20 Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial Sawka, Anna M. Straus, Sharon Rodin, Gary Heus, Lineke Brierley, James D. Tsang, Richard W. Rotstein, Lorne Ezzat, Shereen Segal, Phillip Gafni, Amiram Thorpe, Kevin E. Goldstein, David P. Cancer Original Articles BACKGROUND: Patient decision aids (P‐DAs) inform medical decision making, but longer term effects are unknown. This article describes extended follow‐up from a thyroid cancer treatment P‐DA trial. METHODS: In this single‐center, parallel‐design randomized controlled trial conducted at a Canadian tertiary/quaternary care center, early‐stage thyroid cancer patients from a P‐DA trial were contacted 15 to 23 months after randomization/radioactive iodine (RAI) decision making to evaluate longer term outcomes. It was previously reported that the use of the computerized P‐DA in thyroid cancer patients considering postsurgical RAI treatment significantly improved medical knowledge in comparison with usual care alone. The P‐DA and control groups were compared for the following outcomes: feeling informed about the RAI treatment choice, decision satisfaction, decision regret, cancer‐related worry, and physician trust. In a subgroup of 20 participants, in‐depth interviews were conducted for a qualitative analysis. RESULTS: Ninety‐five percent (70 of 74) of the original population enrolled in follow‐up at a mean of 17.1 months after randomization. P‐DA users perceived themselves to be significantly more 1) informed about the treatment choice (P = .008), 2) aware of options (P = .009), 3) knowledgeable about treatment benefits (P = .020), and 4) knowledgeable about treatment risks/side effects (P = .001) in comparison with controls. There were no significant group differences in decision satisfaction (P = .142), decision regret (P = .199), cancer‐related worry (P = .645), mood (P = .211), or physician trust (P = .764). In the qualitative analysis, the P‐DA was perceived to have increased patient knowledge and confidence in decision making. CONCLUSIONS: The P‐DA improved cancer survivors’ actual and long‐term perceived medical knowledge with no adverse effects. More research on the long‐term outcomes of P‐DA use is needed. Cancer 2015;121:3717–3726. © 2015 American Cancer Society. John Wiley and Sons Inc. 2015-07-20 2015-10-15 /pmc/articles/PMC4832354/ /pubmed/26195199 http://dx.doi.org/10.1002/cncr.29548 Text en © 2015 The Authors. Cancer published by Wiley Periodicals, Inc. on behalf of American Cancer Society. This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial (http://creativecommons.org/licenses/by-nc/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Original Articles
Sawka, Anna M.
Straus, Sharon
Rodin, Gary
Heus, Lineke
Brierley, James D.
Tsang, Richard W.
Rotstein, Lorne
Ezzat, Shereen
Segal, Phillip
Gafni, Amiram
Thorpe, Kevin E.
Goldstein, David P.
Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial
title Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial
title_full Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial
title_fullStr Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial
title_full_unstemmed Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial
title_short Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial
title_sort thyroid cancer patient perceptions of radioactive iodine treatment choice: follow‐up from a decision‐aid randomized trial
topic Original Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4832354/
https://www.ncbi.nlm.nih.gov/pubmed/26195199
http://dx.doi.org/10.1002/cncr.29548
work_keys_str_mv AT sawkaannam thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT straussharon thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT rodingary thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT heuslineke thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT brierleyjamesd thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT tsangrichardw thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT rotsteinlorne thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT ezzatshereen thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT segalphillip thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT gafniamiram thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT thorpekevine thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial
AT goldsteindavidp thyroidcancerpatientperceptionsofradioactiveiodinetreatmentchoicefollowupfromadecisionaidrandomizedtrial